Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
ANTISENSE OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE COMPLEMENTARY TO GAG MESSENGER-RNA BLOCKS REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN HUMAN PERIPHERAL-BLOOD CELLS
Autore:
LISZIEWICZ J; SUN D; WEICHOLD FF; THIERRY AR; LUSSO P; TANG JY; GALLO RC; AGRAWAL S;
Indirizzi:
HYBRIDON INC,1 INNOVAT DR WORCESTER MA 01605 HYBRIDON INC WORCESTER MA 01605 NCI,TUMOR CELL BIOL LAB BETHESDA MD 20892
Titolo Testata:
Proceedings of the National Academy of Sciences of the United Statesof America
fascicolo: 17, volume: 91, anno: 1994,
pagine: 7942 - 7946
SICI:
0027-8424(1994)91:17<7942:AOPCTG>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
CHRONICALLY INFECTED-CELLS; GENE-EXPRESSION; CULTURED-CELLS; OLIGONUCLEOTIDES; INHIBITION; REGION; RNA;
Keywords:
AIDS; THERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
29
Recensione:
Indirizzi per estratti:
Citazione:
J. Lisziewicz et al., "ANTISENSE OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE COMPLEMENTARY TO GAG MESSENGER-RNA BLOCKS REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN HUMAN PERIPHERAL-BLOOD CELLS", Proceedings of the National Academy of Sciences of the United Statesof America, 91(17), 1994, pp. 7942-7946

Abstract

Gene-expression modulator 91 (GEM91) is a 25-nt antisense oligodeoxynucleotide phosphorothioate complementary to the Gag mRNA of human immunodeficiency virus type 1 (HIV-1). Cellular uptake and intracellular distribution of GEM91 within cells suggest that this oligomer is readily available for antisense activity. GEM91 inhibited HIV-1 replication in a dose-dependent and sequence-specific manner. In a comparative study, 2 mu M GEM91 was as effective as 5 mu M 3'-azido-3'-deoxythymidinein blocking virus replication during the 28-day treatment of an HIV-1-infected T-cell line. GEM91 also completely inhibited (> 99%) the growth of three different HIV-1 isolates in primary lymphocytes and prevented the cytopathic effect of the virus in primary CD4(+) T cells. Similarly, treatment with GEM91 for 3 weeks of HIV-1/BaL-infected primarymacrophages blocked virus replication. Based on GEM91 anti-HIV-activity, safety, and pharmacokinetic profile in animals, a clinical trial was started using this compound as an antisense oligonucleotide drug for the treatment of the acquired immunodeficiency syndrome.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 23:56:06